Role of NIMA‐related kinase 2 in lung cancer: Mechanisms and therapeutic prospects
- 2 April 2022
- journal article
- review article
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 36 (5) , 766-776
Abstract
The second most common cancer in both males and females is lung cancer. Chemotherapeutic resistance is the main problem associated with the treatment of lung cancer. Radiation therapy and surgery also produce recurrence in lung cancer patients; this shows the need to develop novel agents acting on new targets. A never in mitosis (NIMA)-related kinase 2 (NEK2) is a serine/threonine kinase associated with the family of NIMA-related kinase (NEK). NEK2 plays an important role in the regulating mitotic processes, such as centrosome duplication and separation, kinetochore attachment, spindle assembly checkpoint, and microtubule stabilization. Several in vitro, in vivo, and clinical studies have confirmed the overexpression of NEK2 in various types of cancers including lung cancer. Overexpression of NEK2 in non-small cell lung cancer (NSCLC) cells increased cell proliferation and chromosomal instability. The overexpression of NEK2 results in the activation of its downstream proteins such as beta-catenin, MAD2, Hec1, rootletin, C-Nap1, CDC20, Cep68, and Sgo1. Activation of the Akt, beta-catenin, and Wnt pathways could promote growth and metastasis of lung cancer cells. Such confirmation suggests that NEK2 is a novel target for treating many cancers including lung cancer. The current review provides an idea about functions and regulation of NEK2 and emphasizes about the role of NEK2 in lung cancer by discussing in vitro, in vivo, and clinical studies pertaining to the same.Keywords
This publication has 44 references indexed in Scilit:
- Centrosomal kinase Nek2 cooperates with oncogenic pathways to promote metastasisOncogenesis, 2013
- Chemotherapy, chemoresistance and the changing treatment landscape for NSCLCLung Cancer, 2011
- Positron Emission Tomography/Computed Tomography and Lymphovascular Invasion Predict Recurrence in Stage I Lung CancersJournal of Thoracic Oncology, 2011
- Treatment of Brain Metastasis from Lung CancerCancers, 2010
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Nek2 targets the mitotic checkpoint proteins Mad2 and Cdc20: A mechanism for aneuploidy in cancerExperimental and Molecular Pathology, 2010
- High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applicationsEuropean Respiratory Journal, 2009
- First- and second-line therapy for advanced nonsmall cell lung cancerEuropean Respiratory Journal, 2009
- Hec1 overexpression hyperactivates the mitotic checkpoint and induces tumor formation in vivoProceedings of the National Academy of Sciences, 2008
- Structure and Regulation of the Human Nek2 Centrosomal KinaseJournal of Biological Chemistry, 2007